Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022
07/28/2022 - 08:47 AM
-- Conference Call Scheduled for 5:00 p.m. ET --
SAN DIEGO , July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows:
Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
About Evofem Biosciences Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data this fall from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for two potential new indications – prevention of chlamydia and prevention of gonorrhea in women. Learn more at phexxi.com and evofem.com .
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact Amy Raskopf Evofem Biosciences, Inc.araskopf@evofem.com (917) 673-5775
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2022-results-and-provide-corporate-update-on-thursday-august-4-2022-301595132.html
SOURCE Evofem Biosciences, Inc.
EVFM Rankings
N/A Ranked by Stock Gains
EVFM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
San Diego
About EVFM
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.